Dimethyl Sulfoxide
Apexbio Technology LLC CPI-169 1450655-76-1 10mM (in 1mL DMSO)
CPI-169 is a selective small-molecule inhibitor targeting enhancer of zeste homolog 2 (EZH2) a catalytic component of polycomb repressive complex 2 (PRC2) By inhibiting EZH2 enzymatic activity CPI-169 suppresses methylation at histone H3 lysine 27 (H3K27me3) thereby altering chromatin structure and gene expression profiles Pharmacological experiments demonstrate inhibition of EZH2 with subnanomolar IC50 values and cellular studies indicate reductions of H3K27 trimethylation at nanomolar concentrations CPI-169 has been utilized experimentally to investigate EZH2-dependent epigenetic processes cell proliferation apoptosis pathways and therapeutic potential particularly in lymphoma and cancer biology studies employing in vitro and in vivo models
Apexbio Technology LLC SCH772984 HCl 942183-80-4 (free base) 10mM (in 1mL DMSO)
SCH772984 HCl is a selective inhibitor targeting extracellular signal-regulated kinases 1 and 2 (ERK1/2) members of the mitogen-activated protein kinase (MAPK) pathway ERK activation is commonly implicated in cancer proliferation particularly in tumors harboring BRAF or RAS mutations SCH772984 HCl binds specifically to ERK1/2 blocking their kinase activity and downstream substrate phosphorylation In cell-based experiments it inhibits phosphorylation of ERK substrates such as p90 ribosomal S6 kinase (RSK) and decreases phosphorylation of ERK1/2 activation-loop residues In vivo SCH772984 HCl reduces tumor growth in xenograft mouse models bearing human melanoma cells with BRAF V600E mutation This compound is widely used in cancer research to study ERK-mediated signaling pathways and models exhibiting resistance to BRAF and MEK inhibitor therapies
AdipoGen DAF-4T Solution 5 mM in DMSO
Chemical. CAS 212558-80-0. Formula C20H7Cl2N3O5. MW 440.19. Fluorescent reference compound for DAF-4 DA CDX-D0216. Spectral data lambdaEx=505nm lambdaEm=530nm.
Apexbio Technology LLC PF-4708671 1255517-76-0 10mM (in 1mL DMSO)
PF-4708671 (CAS 1255517-76-0) is a cell-permeable small molecule that specifically inhibits p70 ribosomal S6 kinase 1 (S6K1) S6K1 regulates diverse cellular processes including protein synthesis and insulin signaling pathways PF-4708671 inhibits S6K1 with an IC50 of 160 nM in HEK293 cell-derived enzyme assays and has a reported Ki value of 20 nM in vitro It selectively inhibits S6K1 over structurally related kinases such as RSK2 and MSK1 hindering phosphorylation of downstream substrates including ribosomal protein S6 mTOR and Rictor PF-4708671 is valuable in biomedical research involving cancer and insulin resistance
Apexbio Technology LLC Methazolamide 554-57-4 10mM (in 1mL DMSO)
Methazolamide (CAS 554-57-4) is a sulfonamide-derived inhibitor of carbonic anhydrase (CA) selectively targeting isoforms CAII and CAIV with IC50 values of 8 1 nM and 80 3 nM respectively By suppressing CA activity methazolamide reduces bicarbonate ion production thus decreasing fluid secretion and intraocular pressure consequently it has clinical use in glaucoma management Recent studies indicate this compound also exhibits insulin-sensitizing properties distinct from other CA inhibitors notably reducing hepatic glucose output suggesting potential applications in diabetes research and metabolic disorders
Apexbio Technology LLC TMP269 1314890-29-3 10mM (in 1mL DMSO)
TMP269 (CAS 1314890-29-3) is a selective inhibitor of class IIa histone deacetylases (HDACs) specifically targeting HDAC isoforms 4 5 7 and 9 with IC50 values of 126 80 36 and 9 nM respectively HDACs catalyze removal of acetyl groups from histone lysine residues thereby condensing chromatin and repressing transcription TMP269 induces moderate cytotoxicity (IC50 22-38 M) in multiple myeloma cell lines correlating with cleavage of caspase-3 -8 -9 and PARP and enhances ER stress-induced apoptosis signaling pathways Additionally TMP269 inhibits PKD1-mediated proliferation in intestinal epithelial IEC-18 cells
Apexbio Technology LLC Entinostat (MS-275,SNDX-275) 209783-80-2 10mM (in 1mL DMSO)
Entinostat (MS-275 SNDX-275 CAS 209783-80-2) is an orally bioavailable small molecule inhibitor targeting histone deacetylases (HDACs) a family of enzymes involved in transcriptional regulation by modifying histone acetylation Specifically entinostat exhibits inhibitory activity against class I HDAC enzymes HDAC1 HDAC3 and HDAC8 with reported IC50 values of 0 368 M 0 501 M and 63 4 M respectively In preclinical investigations entinostat demonstrates anti-proliferative effects in diverse human tumor cell lines including breast colon lung multiple myeloma ovarian pancreatic prostate cancers and leukemia Due to these properties entinostat is widely utilized in oncology research